The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research ...

Non-Alcoholic Steatohepatitis (NASH): Fatty liver with ... Since it is difficult to diagnose NASH without a liver biopsy, the strategy is to identify if fatty liver disease is present and ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

The advent of artificial intelligence (AI) in healthcare is creating waves of innovation, transforming traditional medical practices. One of the ...

The dual agonist of GLP-1 and glucagon, developed in partnership with Zealand Pharma, achieved a biopsy-assessed ... MASH, previously known as non-alcoholic steatohepatitis (NASH) and renamed ...

Research shows weight loss surgery can help reduce the risk of severe liver problems for some patients with MASH.

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Beer is celebrated as one of the most popular and ancient alcoholic beverages globally. The article highlights the historical significance, diverse brewing methods, and worldwide consumption ...